Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Mast cell tryptase as a proinflammatory mediator in late-phase asthmatic response

Mast cell tryptase as a proinflammatory mediator in late-phase asthmatic response Stephen T. Holgate, MD and Sundeep S. Salvi, MD, PhD Mast Cell Tryptase as a Proinflammatory Mediator in Late-Phase Asthmatic Response Salvi SS: Effects of inhibition of mast cell tryptase (P = 0.012) and mean maximum fall in FEV for the LAR by inhaled APC366 (selective tryptase inhibitor) (P = 0.007) after pretreatment with APC366 in comparison on allergen-induced early and late asthmatic with placebo. No significant changes were demonstrated in responses, airway hyperresponsiveness in mild postallergen challenge BHR between the two treatment atopic asthmatics. J Allergy Clin Immunol 2001, periods. Although the EAR was reduced by 18% after 107:1039–1045. treatment with APC366 in comparison with placebo, this was not statistically significant. Rating: •Of importance. Discussion: This study has highlighted the importance of Introduction: Mast cell tryptase is an important mediator mast cell tryptase in the late-phase response in asthmatics implicated in the pathogenesis of asthma. It can induce after challenge with inhaled allergen. Short-term adminis- bronchoconstriction and bronchial hyperresponsiveness tration of APC366 attenuated the LAR but had no signifi- (BHR) and, more recently, has been shown to possess cant effect on EAR and BHR following allergen challenge in important proinflammatory properties. It is released along mild allergic asthmatics. http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Current Allergy and Asthma Reports Springer Journals

Mast cell tryptase as a proinflammatory mediator in late-phase asthmatic response

Download PDF
2 pages

Loading next page...
 
/lp/springer-journals/mast-cell-tryptase-as-a-proinflammatory-mediator-in-late-phase-TrMqrWInrL

References (0)

References for this paper are not available at this time. We will be adding them shortly, thank you for your patience.

Publisher
Springer Journals
Copyright
Copyright © 2002 by Current Science Inc.
Subject
Medicine & Public Health; Allergology; Pneumology/Respiratory System; Otorhinolaryngology; Infectious Diseases
ISSN
1529-7322
eISSN
1534-6315
DOI
10.1007/s11882-002-0004-3
Publisher site
See Article on Publisher Site

Abstract

Stephen T. Holgate, MD and Sundeep S. Salvi, MD, PhD Mast Cell Tryptase as a Proinflammatory Mediator in Late-Phase Asthmatic Response Salvi SS: Effects of inhibition of mast cell tryptase (P = 0.012) and mean maximum fall in FEV for the LAR by inhaled APC366 (selective tryptase inhibitor) (P = 0.007) after pretreatment with APC366 in comparison on allergen-induced early and late asthmatic with placebo. No significant changes were demonstrated in responses, airway hyperresponsiveness in mild postallergen challenge BHR between the two treatment atopic asthmatics. J Allergy Clin Immunol 2001, periods. Although the EAR was reduced by 18% after 107:1039–1045. treatment with APC366 in comparison with placebo, this was not statistically significant. Rating: •Of importance. Discussion: This study has highlighted the importance of Introduction: Mast cell tryptase is an important mediator mast cell tryptase in the late-phase response in asthmatics implicated in the pathogenesis of asthma. It can induce after challenge with inhaled allergen. Short-term adminis- bronchoconstriction and bronchial hyperresponsiveness tration of APC366 attenuated the LAR but had no signifi- (BHR) and, more recently, has been shown to possess cant effect on EAR and BHR following allergen challenge in important proinflammatory properties. It is released along mild allergic asthmatics.

Journal

Current Allergy and Asthma Reports – Springer Journals

Published: May 25, 2002

There are no references for this article.